Arcutis Biotherapeutics, Inc. ARQT Revenue from contracts outside the scope of ASC Topic 606
Revenue from contracts outside the scope of ASC Topic 606 at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueNotFromContractWithCustomer.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of asc topic 606.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606?
- Arcutis Biotherapeutics, Inc. (ARQT) reported revenue from contracts outside the scope of ASC topic 606 of $0 in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606 changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606 decreased by 100.0% year-over-year, from $2M to $0.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606?
- Over 2 years (2023 to 2025), Arcutis Biotherapeutics, Inc.'s revenue from contracts outside the scope of ASC topic 606 has grown at a -63.7% compound annual growth rate (CAGR), from $30.42M to $4M.
- What does revenue from contracts outside the scope of ASC topic 606 mean?
- This metric represents revenue streams recognized outside the standard framework of customer contracts, such as licensing arrangements, government grants, or collaborative research agreements. It provides insight into non-core income sources that supplement primary product sales. Investors use this to evaluate the company's ability to monetize intellectual property or secure alternative funding mechanisms.